Evidence map›Paper›PMID 36266435›Full record

ArticleScientific reports2022

Reduced renal elimination of larger molecules is a strong predictor for mortality.

Erik Herou, Anders Grubb, Alain Dardashti, Shahab Nozohoor, Igor Zindovic, Per Ederoth, Henrik Bjursten

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Erik HerouDepartment of Cardiothoracic Surgery, Skåne University Hospital, 221 85, Lund, Sweden. erik.herou@med.lu.se.
Anders GrubbDepartment of Clinical Chemistry, Skåne University Hospital, Lund, Sweden.
Alain DardashtiDepartment of Cardiothoracic Surgery, Skåne University Hospital, 221 85, Lund, Sweden.
Shahab NozohoorDepartment of Cardiothoracic Surgery, Skåne University Hospital, 221 85, Lund, Sweden.
Igor ZindovicDepartment of Cardiothoracic Surgery, Skåne University Hospital, 221 85, Lund, Sweden.
Per EderothDepartment of Cardiothoracic Surgery, Skåne University Hospital, 221 85, Lund, Sweden.
Henrik BjurstenDepartment of Cardiothoracic Surgery, Skåne University Hospital, 221 85, Lund, Sweden.
Skåne University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal dysfunction is a major risk factor for premature death and has been studied extensively. A new renal syndrome, shrunken pore syndrome (SPS), confers higher mortality in all studied populations. SPS is a condition in which cystatin C-based estimation of glomerular filtration rate (eGFR

Indexed as

Cystatin CKidney DiseasesCohort StudiesCreatinineHumansRenal EliminationRetrospective StudiesCreatinineCystatin C

Identifiers

PMID36266435
PMCPMC9584920
OpenAlexW4306871196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.